Standard Family Office’s Alnylam Pharmaceuticals ALNY Stock Holding History

Standard Family Office’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-29	Closed	-$6K	–	29
2022 Q3	$6K	Hold	29	–	–	﹤0.01%	285
2022 Q2	$4K	Buy	+29	New	+$4.11K	0.04%	127
2022 Q1	–	Sell	-40	Closed	-$7K	–	82
2021 Q4	$7K	Buy	+40	New	+$7.43K	0.06%	127
2021 Q3	–	Sell	-13	Closed	-$2K	–	88
2021 Q2	$2K	Buy	+13	New	+$1.9K	﹤0.01%	335
2021 Q1	–	Sell	-11	Closed	-$1K	–	617
2020 Q4	$1K	Buy	+11	New	+$1.47K	﹤0.01%	530

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Standard Family Office's ALNY Position: Q4 2022 in Review

Standard Family Office sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2022, closing a stake of 29 shares — an estimated $6K sold.

Standard Family Office first reported a position in ALNY in Q4 2020 and held it in 5 quarters. The position peaked at $7K in Q4 2021. 487 funds tracked by Wall St. Rank hold ALNY as of Q4 2022.

Standard Family Office reported no remaining Alnylam Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Standard Family Office sold 29 Alnylam Pharmaceuticals shares in Q4 2022, an estimated $6K.
Standard Family Office first reported a position in Alnylam Pharmaceuticals in Q4 2020 and held it in 5 quarters.
Standard Family Office's Alnylam Pharmaceuticals position peaked at $7K in Q4 2021.
487 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2022.

Based on Standard Family Office's 13F filing for Q4 2022, filed 13 Feb 2023.